Advertisement
Advertisement

TNXP

TNXP logo

Tonix Pharmaceuticals Holding Corp.

16.34
USD
Sponsored
+1.39
+9.30%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

16.55

+0.21
+1.28%

TNXP Earnings Reports

Positive Surprise Ratio

TNXP beat 21 of 40 last estimates.

53%

Next Report

Date of Next Report
Mar 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
$3.03M
/
-$3.25
Implied change from Q3 25 (Revenue/ EPS)
-8.02%
/
-9.47%
Implied change from Q4 24 (Revenue/ EPS)
+17.20%
/
-66.73%

Tonix Pharmaceuticals Holding Corp. earnings per share and revenue

On Nov 10, 2025, TNXP reported earnings of -3.59 USD per share (EPS) for Q3 25, beating the estimate of -3.65 USD, resulting in a 1.82% surprise. Revenue reached 3.29 million, compared to an expected 3.16 million, with a 4.05% difference. The market reacted with a +4.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -3.25 USD, with revenue projected to reach 3.03 million USD, implying an decrease of -9.47% EPS, and decrease of -8.02% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Tonix Pharmaceuticals Holding Corp. reported EPS of -$3.59, beating estimates by 1.82%, and revenue of $3.29M, 4.05% above expectations.
The stock price moved up 4.1%, changed from $16.84 before the earnings release to $17.53 the day after.
The next earning report is scheduled for Mar 16, 2026.
Based on 5 analysts, Tonix Pharmaceuticals Holding Corp. is expected to report EPS of -$3.25 and revenue of $3.03M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement